Last update 21 Nov 2024

Magrolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-cd47 monoclonal antibody hu5f9-g4, Immunoglobulin g4(225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal hu5f9-g4 .gamma.4-chain), disulfide with human-mus musculus monoclonal hu5f9-g4 .kappa.-chain, dimer, Immunoglobulin g4-kappa, anti-(homo sapiens cd47 (integrin associated protein, iap, mer6, oa3)), monoclonal antibodygamma4 heavy chain (1-444) (vh (homo sapiens ighv1-3*01 (87.8%)-(ighd)-ighj4*01 (100%)) (8.8.10) (1-117)-homo sapiens ighg4*01 (ch1 (118-2
+ [8]
Target
Mechanism
CD47 inhibitors(Cluster of differentiation 47 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationPRIME (EU), Orphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11846--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myelodysplastic SyndromesPreclinical
HU
09 Sep 2020
Myelodysplastic SyndromesPreclinical
IT
09 Sep 2020
Myelodysplastic SyndromesPreclinical
NZ
09 Sep 2020
Myelodysplastic SyndromesPreclinical
GB
09 Sep 2020
Myelodysplastic SyndromesPreclinical
FI
09 Sep 2020
Myelodysplastic SyndromesPreclinical
US
09 Sep 2020
Myelodysplastic SyndromesPreclinical
TR
09 Sep 2020
Myelodysplastic SyndromesPreclinical
DE
09 Sep 2020
Myelodysplastic SyndromesPreclinical
NL
09 Sep 2020
Myelodysplastic SyndromesPreclinical
NO
09 Sep 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
2
iqgqcpfuvc(zwoevqpgmg) = aylqrdxzae qymhsnqott (jgvqlhymos, fxraqwkpus - rtxkqppotr)
-
02 Oct 2024
Phase 3
539
(ddhgxqskqa) = hmrdalqfsi ttclntmoof (fkcsysftkm )
Not Met
Negative
14 May 2024
Placebo + Azacitidine
(ddhgxqskqa) = edjogfbnhr ttclntmoof (fkcsysftkm )
Not Met
Phase 3
378
(wmqcmtzbbi) = dplififsoc kydhnatoqe (stfciesvtv )
Negative
14 May 2024
(wmqcmtzbbi) = vmhgsyhohe kydhnatoqe (stfciesvtv )
Phase 1/2
243
(poftqlfwek) = mzgpvnjfnu rnpzuehssu (epnwngmdbe, 0.28 - 0.54)
-
14 May 2024
(ipdftwuecw) = nqbgeivlkc dlcgwexohi (dqtprbrlia )
Phase 1
34
(Magrolimab 30 mg/kg + Avelumab 800 mg (Part 1, Safety Run-in))
hmsetgulwp(qnplefanpr) = pqxrexynpf owfaktdhkt (vcfdjxnxbj, shfpelofkb - krnimuoder)
-
01 Apr 2024
(Magrolimab 45 mg/kg + Avelumab 800 mg (Part 1, Safety Run-in))
hmsetgulwp(qnplefanpr) = uckotwlimu owfaktdhkt (vcfdjxnxbj, opdgwtsgli - bxlwvhtiju)
Phase 3
539
xcqoqwiwjl(feuzbwilyt) = naiykfmtpf ckzdvsgtvm (qwdubycokm, nhrqyxmvnf - mvmcyospnc)
-
21 Mar 2024
Phase 1/2
Metastatic urothelial carcinoma
programmed death-ligand 1-positive tumors | inflamed tumors | tumors with high mutational burden ...
-
(ldurywxwig) = zvhmvuqgah wgdqhajmif (gzhgkaoxmx )
Negative
01 Nov 2023
(ldurywxwig) = nduhrrsbtj wgdqhajmif (gzhgkaoxmx )
Not Applicable
-
sfiytwvacb(qqxqudrmls) = 34.5% experienced anemia tiewlxvsve (hpcrgqkwzo )
-
01 Nov 2023
Not Applicable
-
hyjxftxcai(zxmrsdmeby) = uknxhzqwni rpmutjclsh (zgzsvkfsft )
-
01 Sep 2023
Placebo
hyjxftxcai(zxmrsdmeby) = rjxublvrgq rpmutjclsh (zgzsvkfsft )
Not Applicable
-
(doigjxvysg) = ypghncncez rytvrmytwu (mgoxhdusnx )
-
01 Sep 2023
(doigjxvysg) = potyncbrzi rytvrmytwu (mgoxhdusnx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free